论文部分内容阅读
目的:评估布地奈德/福莫特罗(budesonide/formoterol,BUD/FM)吸入治疗老年支气管哮喘患者的长期安全性。方法:回顾性分析2011年5月-2013年9月连续应用疗BUD/FM吸入(160/4.5毫克,2吸,每日两次)治的123例老年哮喘患者的临床资料,观察治疗过程中血钾和脉率的变化。结果:患者的平均年龄为74岁,65-74岁及≥75岁的患者分别占45.5%和54.5%,与治疗前比较,血钾及脉率在治疗后1个月、6个月及12个月无明显改变,P>0.05;但脉率在≥75岁组的治疗后6个月时明显下降,P<0.05。结论:长期应用常用剂量的BUD/FM对老年哮喘患者的血钾水平和脉率无长期不良影响。
OBJECTIVE: To evaluate the long-term safety of inhaled budesonide / formoterol (BUD / FM) in elderly patients with bronchial asthma. Methods: The clinical data of 123 elderly patients with asthma treated with continuous BUD / FM inhalation (160 / 4.5 mg, 2 inhalation twice daily) from May 2011 to September 2013 were retrospectively analyzed. The duration of treatment Changes in serum potassium and pulse rate. Results: The average age of patients was 74 years old, 45.5% and 54.5% were 65-74 years old and ≥75 years old respectively. Compared with those before treatment, the serum potassium and pulse rate were significantly higher at 1 month, 6 months and 12 months after treatment There was no significant change in one month, P> 0.05; however, the pulse rate decreased significantly at 6 months after treatment in the group of ≥75 years, P <0.05. CONCLUSIONS: The long-term use of conventional doses of BUD / FM has no long-term adverse effects on serum potassium levels and pulse rate in elderly patients with asthma.